ORIC-114

The pharmaceutical sector has seen significant advancements with FDA approvals for new treatments and the initiation of clinical trials for innovative therapies. Notably, Eli Lilly's Omvoh has been approved for Crohn's disease, and Johnson & Johnson is advancing its TAR-200 for bladder cancer treatment. These developments underscore the industry's commitment to addressing unmet medical needs through research and innovation.

ORIC Pharmaceuticals reported encouraging early data from a Phase 1b trial of ORIC-944 combined with apalutamide in metastatic castration-resistant prostate cancer (mCRPC).

Oncolytics Biotech presented data at the ASCO GI Symposium, highlighting pelareorep's potential in treating relapsed anal and metastatic pancreatic cancers.

ORIC Pharmaceuticals' drug candidate ORIC-114 has shown promising preclinical results for treating non-small cell lung cancer with specific mutations, demonstrating superior potency and selectivity. The drug is currently under evaluation in a global clinical trial, with updated data anticipated in the first half of 2025.

Stifel has initiated coverage on ORIC Pharmaceuticals with a Buy rating and a $20 price target, highlighting the company's potential in prostate cancer treatments, especially its ORIC-944 product expected to enter phase 3 trials in 2025. ORIC Pharmaceuticals is noted for its innovative approach to treating metastatic castration-resistant prostate cancer, with ORIC-944 utilizing PRC2 inhibition in combination with androgen receptor pathway inhibitors.